FDA tightens advisory group criteria

Share this article:
A significant number of current FDA advisory committee members would be disqualified from participating in future panel deliberations under new guidelines proposed in an agency draft guidance document.

The FDA says it does not yet have an exact number for how many current panel members would be impacted by the new guidelines, the agency is interested in hearing how the new guidelines will affect current members.

Where current guidelines allow waivers in certain situations, the new guidelines generally disqualify members with financial ties exceeding $50,000—no participation and no voting. Members whose financial ties are less than $50,000 would be allowed to participate but would have suspended voting privileges. Members with no conflicts would be allowed full participation.

The FDA also says it intends to “generally limit participation in certain cases where there may be a perception of a conflict of interest, even though full participation would be permitted under the applicable statutes.”

A CBS News analysis found that since 2002 medical professionals had registered 189 conflicts of interest at 86 advisory committee meetings.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...